Bristol-Myers Squibb is in talks to sell its consumer over-the-counter drug line, which includes Excedrin and Bufferin, according to news reports.
The company hopes to sell off non-core consumer products to focus on drugs to teat and prevent disease, The New York Times reported yesterday. The sale could fetch as much as $1billion, the paper said.
The deal could happen fast, with GlaxoSmithKline and some private equity firms reported to be interested.
The sale would also include the brands Comtrex, a cold medicine, and Keri lotions.